Caplin Point Labs Share Price

Overview 

Caplin Point Laboratories Limited, with its corporate operations in Chennai, functions as a pharmaceutical company engaged in the manufacturing and marketing of generic formulations and branded products. Caplin Point Laboratories provides a comprehensive range of pharmaceutical products including tablets, capsules, injections (liquid and lyophilized, pre-filled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. Caplin Point Laboratories share price on NSE and BSE signifies how market participants react to the company‘s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on demand for generic formulations, regulatory approvals, expansion into regulated markets, product pipeline development, and the performance of its key markets spanning Latin America, Africa, and the United States. 

Caplin Point Laboratories stock price is influenced by various factors such as earnings, fluctuations in currency exchange rates, regulatory changes in international markets, and USFDA approvals. In the longer run, strategies such as expanding into complex injectables, entering the US market, and deepening presence in Latin America and Africa affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company‘s stock price movements. 

Caplin Point Laboratories live share price provides real time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Caplin Point Laboratories live price helps in observing short term price volatility and shows how a stock moves relative to the broader BSE Healthcare index and the pharmaceutical sector. 

Furthermore, monitoring Caplin Point Laboratories stock price movements helps investors understand real time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short term performance, and respond to news, quarterly results, or sector trends that may influence the company‘s valuation and overall investment outlook. 

Caplin Point Laboratories Limited Company Fundamentals 

A. Company Background

Caplin Point Laboratories Limited was incorporated on 16th April 1990 as a private limited company. The company is engaged in the manufacturing and sourcing of APIs, finished formulations, research and development, and clinical research with presence in Latin America, Africa, USA and other nations. It operates primarily in the pharmaceutical formulations segment, supplying solutions such as generic formulations, branded products, and active pharmaceutical ingredients. Its operations are based in India, with four manufacturing sites and three research and development facilities. Over time, the company has built a portfolio of over 4,000 registered licenses and 650 formulations across 36 therapeutic areas. 

B. Company Product Lines

• Oral Formulations 

• Offers tablets, capsules, liquid orals, and soft gel capsules. 

• Injectable Formulations 

• Provides liquid and lyophilized injections, pre-filled syringes, and powders for injections. 

• Topical Formulations 

• Supplies ointments, creams, gels, and other external applications. 

• Other Pharmaceutical Products 

• Offers ophthalmic solutions, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. 

The product portfolio includes more than 65% of the drugs on the WHO essential drug list. 

C. Company Revenue Model

• Emerging Markets Sales 

• Revenue generated through pharmaceutical product sales to Latin American and African countries, accounting for approximately 79-83% of revenue. 

• Regulated Markets Sales 

• Contribution from the United States and other regulated markets, accounting for approximately 21% of revenue. 

• Branded and Generic Sales 

• Revenue from both branded products and generic formulations across various therapeutic areas. 

Revenue performance is primarily influenced by demand for generic pharmaceuticals, regulatory approvals, and pricing realizations in emerging and regulated markets. 

D. Geographic Presence

• Corporate Headquarters 

• Primary administrative and management functions based in Chennai, Tamil Nadu, India. 

• Manufacturing Operations 

• Four manufacturing sites located in India. 

• Research and Development 

• Three R&D facilities supporting product development and clinical research. 

• International Presence 

• Strong presence in Latin America, Francophone Africa, and the United States. 

E. Key Milestones

• 1990 – Incorporation: Caplin Point Laboratories was incorporated on 16th April 1990. 

• 1994 – IPO and Listing: The company was listed following an Initial Public Offering that was oversubscribed 117 times. 

• 2014 – Forbes Recognition: Caplin Point Lab was listed on Forbes Asia‘s ‘200 Best Billion’. 

• Regulatory Approvals: The company received USFDA and EU-GMP approvals for its injectable facility. 

• Expansion into Regulated Markets: The company expanded its presence into the United States with over 40 US approvals and a 60-plus product pipeline. 

• Growth in Emerging Markets: Established a front-end generic presence in Latin America and brand marketing in Francophone Africa. 

• Strategic Focus on Complex Injectables: The company developed an organic R&D pipeline of over 60 products spanning injectables, ophthalmics, oncology, unit-dose and other complex segments. 

• Capacity Expansion: The company pursued aggressive capacity expansion to support growth in regulated markets. 

F. Industry Perspective

The pharmaceutical industry, where Caplin Point Laboratories operates, is one of the world‘s largest and fastest-growing sectors. The global pharmaceutical market was valued at approximately US$1.8 trillion in 2025 and is projected to reach US$2.5 trillion by 2030, growing at a CAGR of 6-7%. The global generic drugs market is expected to expand from US$450 billion in 2025 to over US$650 billion by 2032, registering a CAGR of approximately 5-6%, driven by rising healthcare costs, patent expiries, and increasing demand for affordable medicines. India accounts for approximately 20% of global generic drug exports and remains the world’s largest provider of generic medicines. According to the Indian Pharmaceutical Alliance, the Indian pharmaceutical industry generated approximately US$50 billion in FY24, growing 8-10% YoY, and is expected to reach US$130 billion by 2030, implying a CAGR of around 15-17%. Pharmaceutical exports from India contribute over US$28 billion annually, with the sector employing more than 3 million professionals. The domestic pharmaceutical market in India is valued at approximately US$42 billion and is growing at 10-12% annually. Growth is supported by increasing healthcare expenditure, government initiatives such as the Production Linked Incentive scheme for pharmaceuticals, and rising demand for generic medicines globally. The PLI scheme for pharmaceuticals aims to boost domestic manufacturing of active pharmaceutical ingredients and key starting materials. However, pricing pressure, regulatory challenges, geopolitical uncertainties, and supply chain disruptions remain key industry challenges. The injectables segment, where Caplin Point Laboratories has a strong presence, is experiencing faster growth due to increasing demand for biologics, biosimilars, and complex generics. The US generic drug market, valued at approximately US$110 billion, continues to offer significant opportunities for Indian pharmaceutical companies with USFDA-approved facilities. 

Caplin Point Laboratories Limited Stock Market Presence: Listings & Index Representation 

Caplin Point Laboratories Limited is listed on the National Stock Exchange (NSE) under the ticker symbol CAPLIPOINT and on the Bombay Stock Exchange (BSE) with the scrip code 524742. Caplin Point Laboratories share price is actively traded on both exchanges, making it one of the most closely followed mid-cap pharmaceutical stocks in India. The company has established a strong presence in the Indian equity market, with Caplin Point Laboratories share price frequently monitored by retail and institutional investors seeking exposure to the pharmaceutical formulations and generic drugs sector. 

As one of India‘s prominent pharmaceutical companies by market capitalisation, Caplin Point Laboratories Limited is a constituent of several benchmark and sectoral indices, including the BSE 500, BSE Healthcare, and other broader market indices. The Caplin Point Laboratories stock price carries significant weight in these indices, reflecting the company’s leadership in the emerging markets-focused pharmaceutical sector and its influence on broader market performance within the healthcare segment. Investors often track Caplin Point Laboratories stock price alongside major benchmark indices to evaluate the company‘s performance relative to its peers and the overall market. 

The company’s extensive index representation enhances its visibility among domestic and international investors, including mutual funds, exchange-traded funds (ETFs), pension funds, and foreign institutional investors. Owing to its strong market capitalisation, liquidity, and consistent financial performance, Caplin Point Laboratories Limited is widely regarded as a quality player in India‘s pharmaceutical industry. Its stock remains a key component in diversified investment portfolios, while movements in the company’s share value are often viewed as an indicator of broader trends within the Indian pharmaceutical sector. 

Caplin Point Laboratories Limited Stock Performance and Share Price History 

Caplin Point Laboratories share price on the NSE reflects the company‘s position as a leading pharmaceutical company with a strong focus on emerging markets and expanding presence in regulated markets. The performance of Caplin Point Laboratories stock price is primarily influenced by regulatory approvals, product launches, expansion into the US market, client retention, operating margin trends, and growth in injectables and complex generics. Investors closely monitor Caplin Point Laboratories share price alongside other mid-cap pharmaceutical companies to assess the sector’s relative performance and valuation. Earnings announcements, management guidance and regulatory developments continue to influence Caplin Point Laboratories share price across different market cycles. 

Investors closely monitor the Caplin Point Laboratories stock price to evaluate the company‘s competitive position within the Indian pharmaceutical sector and compare its performance with other mid-cap pharmaceutical companies. Earnings announcements, management guidance, and global regulatory developments remain key factors influencing investor expectations. 

Corporate initiatives, including investments in complex injectables, expansion into the US market, and R&D pipeline development, have also shaped expectations surrounding Caplin Point Laboratories share price. Although these strategic initiatives strengthen the company’s long-term outlook, they may trigger short-term volatility depending on regulatory approvals and market conditions. The Caplin Point Laboratories stock price is also influenced by factors such as currency fluctuations, operating margin trends, and the pace of regulatory approvals in key markets. Strong revenue growth and consistent execution often support the company‘s valuation over the long term. 

While day-to-day movements are generally driven by news flow and quarterly earnings, long-term valuation is better assessed through annual highs and lows, which reflect changes in pharmaceutical demand, earnings visibility, and overall business performance. As a result, Caplin Point Laboratories stock price continues to be closely tracked by domestic and global investors seeking exposure to India’s pharmaceutical sector. 

As of recent trading data, Caplin Point Laboratories share price trades around ₹1,692-2,538, compared with its 52-week high of ₹2,397-2,659.70, while the 52-week low stands at ₹1,551-2,001.50, indicating a correction from the peak. The share price has shown resilience compared to many mid-cap pharmaceutical companies because of the company‘s diversified geographic presence, strong balance sheet and focus on high-growth emerging markets. 

The company’s revenue performance remains closely linked to pharmaceutical demand in Latin America, Africa, and the United States. Strong regulatory approvals, product pipeline development and market expansion have historically supported Caplin Point Laboratories share price, whereas slower regulatory approvals, pricing pressure and currency fluctuations have resulted in periods of consolidation. In addition, R&D investments and capacity expansion costs have periodically weighed on Caplin Point Laboratories share price. 

Caplin Point Laboratories stock price also responds to broader market sentiment, quarterly earnings and management commentary. Historically, Caplin Point Laboratories stock price has remained sensitive to USFDA inspections, regulatory policies, currency fluctuations and global pharmaceutical trends. Changes in foreign institutional investor flows, pricing pressure in key markets, and margin trends have periodically affected Caplin Point Laboratories stock price, while continued investments in injectables, complex generics, and R&D remain important long-term drivers for Caplin Point Laboratories stock price. 

Examining the long-term trend, Caplin Point Laboratories share price has delivered significant wealth creation over the past decade. Based on annual closing levels, Caplin Point Laboratories share price has demonstrated strong growth, with the stock delivering a 10-year return of approximately 695.7-2,767%. The stock price CAGR over 10 years stands at approximately 23.1%. The company’s market value has grown from ₹6.08 billion in 2014 to ₹151.07 billion, representing a total increase of 2,383% and an annual compound growth rate (CAGR) of 35.42%. 

From a seasonality perspective, Caplin Point Laboratories share price has generally performed better during quarters with strong regulatory approvals and product launches. Historical data also indicates that Caplin Point Laboratories share price has typically delivered stronger annual returns following periods of market expansion and regulatory successes. 

Performance analysis shows that Caplin Point Laboratories share price generally benefits from a weaker rupee as export revenue increases in rupee terms. Conversely, pricing pressure, regulatory delays and currency fluctuations can compress operating margins and influence investor sentiment. 

Over the last 10 years, Caplin Point Laboratories has delivered a cumulative return of approximately 695.7-2,767%, significantly outperforming the broader market indices. The stock price CAGR over 10 years stands at approximately 23.1%, while the 5-year CAGR is approximately 30.1%. Over the past three years, the stock has delivered returns of approximately 157.2-165.7%, while one-year returns have declined approximately 11.29-19.1%. Three-month and six-month returns stand at approximately -15.3% and -22.4%, respectively. 

In the short term, Caplin Point Laboratories share price has shown mixed performance. The stock has experienced correction from its highs but continues to trade significantly above its 10-year low. During the past year, Caplin Point Laboratories touched a high of approximately ₹2,659.70 and a low of approximately ₹2,001.50, illustrating the volatility experienced in recent quarters despite the stock‘s strong long-term positive return profile. 

Caplin Point Laboratories Limited Investor Relevance and Role in Portfolio 

Caplin Point Laboratories Limited is a prominent holding in mid-cap and pharmaceutical sector portfolios, providing investors with exposure to generic formulations, injectables, emerging market pharmaceuticals, and regulated market expansion. Caplin Point Laboratories share price is closely followed by market participants seeking exposure to India‘s pharmaceutical sector, as the company remains one of the country’s most established pharmaceutical companies with a diversified geographic presence. 

The company‘s inclusion in major benchmark indices, including the BSE 500 and BSE Healthcare, reinforces its significance within India’s pharmaceutical ecosystem. Caplin Point Laboratories stock price is widely tracked by domestic and international institutional investors, mutual funds, and exchange-traded funds (ETFs) because of its market capitalisation, strong liquidity, and consistent presence in benchmark portfolios. 

In addition, the company‘s strong balance sheet, consistent cash generation, and established leadership in emerging market pharmaceuticals make it a key constituent in diversified equity portfolios. Consequently, Caplin Point Laboratories stock price remains an important indicator for investors assessing trends in the Indian pharmaceutical sector and the broader healthcare industry. 

Caplin Point Laboratories share price is influenced by the company’s ownership structure. Caplin Point Laboratories‘ equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. The company has a market capitalisation of approximately ₹12,862-20,306 crore. The company‘s management includes experienced professionals driving the pharmaceutical business. This investor base underscores the company’s role as a holding in both domestic and international portfolios concentrating on pharmaceuticals and healthcare. 

Beyond fundamentals and ownership, Caplin Point Laboratories share price is actively monitored in cash and derivatives market segments, where trading volumes and delivery patterns reflect expectations on regulatory approvals, product launches, and market conditions. Caplin Point Laboratories stock price is available for trading on both major Indian exchanges, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements. 

Technical indicators provide additional insight into short term momentum shifts in Caplin Point Laboratories share price. While these indicators are primarily used for near term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, the stock‘s beta indicates moderate volatility compared to the broader market. The company is almost debt free, reflecting a strong balance sheet. 

Based on available data, the stock’s beta indicates moderate volatility compared to the broader market. For the long-term range (monthly tick over 4 years, with NIFTY50 as base), the beta is 1.06, the mean is 3409.80, and the standard deviation is 5.90. For the daily one month range, the beta is 1.81, the mean is 2126.46, and the standard deviation is 1.98. For the daily three month range, the beta is 0.982, the mean is 2315.30, and the standard deviation is 2.22. For the weekly one year range, the beta is 0.977, the mean is 2815.92, and the standard deviation is 2.96. For the weekly two year range, the beta is 0.903, the mean is 3379.38, and the standard deviation is 3.05. For the 2 week two year range, the beta is 1.03, the mean is 3368.66, and the standard deviation is 4.49. For the monthly two year range, the beta is 1.13, the mean is 3299.01, and the standard deviation is 6.55. The company has effectively no debt, reflecting a strong balance sheet with net cash position. 

Overall, Caplin Point Laboratories demonstrates a moderate volatility profile compared to the broader market, with the stock generally considered to have stable systematic risk. This makes it less sensitive to broader market movements compared to smaller pharmaceutical companies, though it remains exposed to sector specific factors such as regulatory approvals and currency fluctuations. 

Caplin Point Laboratories Limited Sectoral Relevance and Peer Positioning 

Caplin Point Laboratories Limited sector relevance stems from its three decade presence in the pharmaceutical industry, its position as a leading pharmaceutical company with a strong focus on emerging markets, and its expanding presence in regulated markets. Peer comparisons with companies like Sun Pharma, Divi‘s Laboratories, Torrent Pharma, Cipla, and Dr Reddy‘s Laboratories focus on revenue growth, margin performance, regulatory approvals, and R&D pipeline rather than short term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of pharmaceutical trends, regulatory developments, and pricing policies further highlights Caplin Point Laboratories positioning within the broader global pharmaceutical market. 

Caplin Point Laboratories market cap highlights its position as a mid-cap player within the global pharmaceutical sector. The company‘s market capitalization has moved in line with investor perceptions of the company’s growth potential following its strategic pivot to injectables and regulated markets. Examining Caplin Point Laboratories‘ market capitalization history reveals a pattern of substantial growth. In 2014, the market cap stood at ₹6.08 billion, before rising steadily over the years. The market cap grew to approximately ₹45,234 crore in 2023 and increased to approximately ₹99,000 crore in 2024. The current market cap stands at approximately ₹12,862-20,306 crore. Over this ten-year period, Caplin Point Laboratories’ market cap has experienced a compound annual growth rate of approximately 35.42%, reflecting the company‘s ability to create substantial shareholder value. 

Caplin Point Laboratories earnings trajectory demonstrates the impact of its operational execution in a competitive industry. In recent fiscal years, total income showed trends supported by the core pharmaceutical formulations business. The company’s revenue from operations increased from ₹625.09 crore to ₹752.41 crore. Total income increased from ₹730.93 crore to ₹887.00 crore over the same period. Caplin Point Laboratories earnings, measured by profit after tax, have demonstrated consistent growth over the past decade, reflecting the company‘s operational strength and market leadership. Net profit has grown from ₹215.08 crore to ₹461.42 crore over recent periods. Over the past decade, Caplin Point Laboratories earnings have grown significantly, driven by strong performance in emerging markets and expansion into regulated markets. 

Caplin Point Laboratories EPS reflects its operational performance and ability to generate consistent profits from its pharmaceutical business. Basic EPS has shown steady growth, increasing from ₹20.65 to ₹44.67. Over the past decade, EPS has grown substantially, representing a compound annual growth rate that reflects the company’s strong profitability, effective capital management, and resilience despite global economic uncertainties and changing regulatory environments in the pharmaceutical industry. 

Caplin Point Laboratories P/E ratio reflects investor expectations of the company‘s earnings growth and future prospects. The ratio has fluctuated over the years in response to changing market sentiment, industry conditions, and business performance. The P/E ratio was 12.13 in 2022, increased to 17.32 in 2021, reached 21.99 in 2023, and stood at 28.51 in 2024. The current trailing P/E ratio stands at approximately 28.51-36.48, while the price-to-book ratio is approximately 5.34. The recent increase in valuation reflects the company’s strong earnings growth and expansion into regulated markets. 

Summary 

Caplin Point Laboratories Limited operates in the pharmaceutical sector with a strong presence in emerging markets and expanding footprint in regulated markets. Caplin Point Laboratories share price reflects the company‘s consistent performance in the pharmaceutical industry. The company has developed a strong product portfolio with over 4,000 registered licenses. Caplin Point Laboratories stock price movements are influenced by regulatory approvals and market expansion.